Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment

– Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 – – Phase 3 SENTRY Results Selected for Late-Breaking Oral Presentation at ASCO on June 2 – – Total Revenue was $35.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $29....

Read More